What's in MGC Pharmaceuticals d.o.o's pipeline?

MGC Pharmaceuticals d.o.o has 3 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with MGC Pharmaceuticals d.o.o's portfolio?

Top competitors by shared drug class: Hurd,Yasmin, Ph.D..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mgc-pharmaceuticals-d-o-o.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

MGC Pharmaceuticals d.o.o — Portfolio Competitive Intelligence Brief

MGC Pharmaceuticals d.o.o pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ArtemiC	ArtemiC	marketed	Cannabis-derived pharmaceutical
CimetrA-2	CimetrA-2	phase 3	cannabinoid receptor agonist	CB1/CB2 receptors	Pain management
CimetrA-1	CimetrA-1	phase 3	Cannabinoid therapeutic		Neurology / Immunology

Therapeutic area mix

Neurology / Immunology · 1
Pain management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hurd,Yasmin, Ph.D. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MGC Pharmaceuticals d.o.o:

Cite this brief

Drug Landscape (2026). MGC Pharmaceuticals d.o.o — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mgc-pharmaceuticals-d-o-o. Accessed 2026-05-16.